ライフサイエンスコーパス: bullous pemphigoid

1 ermal blistering disease that closely mimics bullous pemphigoid.

2 associated with the blistering skin disease, bullous pemphigoid.

3 e relevant in the diagnosis and treatment of bullous pemphigoid.

4 pemphigoid and help distinguishing them from bullous pemphigoid.

5 nd for the clinical benefit of patients with bullous pemphigoid.

6 ut blisters had immunopathologic findings of bullous pemphigoid.

7 hout skin lesions can be the only symptom of bullous pemphigoid.

8 dase-IV inhibitor-associated noninflammatory bullous pemphigoid.

9 en of the autoimmune skin blistering disease bullous pemphigoid.

10 as valuable medications in the treatment of bullous pemphigoid.

11 s in a mouse model of the autoimmune disease bullous pemphigoid.

12 in NC16A are involved in the pathogenesis of bullous pemphigoid.

13 he development of the autoimmune response in bullous pemphigoid.

14 ibodies directed against the NC16A domain of bullous pemphigoid 180 (collagen XVII), a transmembrane

15 s that bind to this immunodominant region of bullous pemphigoid 180 are capable of inducing a skin di

16 d patients, all of whom had circulating anti-bullous pemphigoid 180 autoantibodies, showed a specific

17 nic target of autoantibodies associated with bullous pemphigoid, a blistering skin disease.

18 mice would also be resistant to experimental bullous pemphigoid, a disease with a pathogenesis though

19 ned autoantibody-reactive site recognized by bullous pemphigoid and herpes gestationis sera) and the

20 th two other autoimmune blistering diseases, bullous pemphigoid and herpes gestationis.

21 ednisolone for short-term blister control in bullous pemphigoid and significantly safer in the long-t

22 , pemphigus foliaceous, pemphigus, vulgaris, bullous pemphigoid, and benign chronic pemphigus, howeve

23 vulgaris were diagnosed; there was 1 case of bullous pemphigoid; and 1 suspected case of paraneoplast

24 These mice represent a bullous pemphigoid animal model featuring pruritus in im

25 esmosomal transmembrane protein, the 180 kDa bullous pemphigoid antigen (BP180), also known as type X

26 n utilizing primers specific for the 230 kDa bullous pemphigoid antigen (BPAG1), the 180 kDa bullous

27 The 180-kDa bullous pemphigoid antigen (BPAG2) is a candidate gene/p

28 lous pemphigoid antigen (BPAG1), the 180 kDa bullous pemphigoid antigen (BPAG2), the alpha6 and beta4

29 mma, activated the skin-specific promoter of bullous pemphigoid antigen 1 (BPAG-1).

30 Bullous pemphigoid antigen 1 (BPAG1) is a member of the

31 Bullous pemphigoid antigen 1 (BPAG1) is a member of the

32 They contain mutations in the gene encoding Bullous Pemphigoid Antigen 1 (BPAG1), or dystonin.

33 Bullous pemphigoid antigen 1 (BPAG1-e, also known as BP2

34 and is identical to the neuronal isoform of bullous pemphigoid antigen 1 (BPAG1-n).

35 Other plakins, such as bullous pemphigoid antigen 1 and microtubule and actin c

36 Disruption of the BPAG1 (bullous pemphigoid antigen 1) gene results in progressiv

37 proteins, to which envoplakin, desmoplakin, bullous pemphigoid antigen 1, and plectin belong.

38 led-coil domain of the epithelial isoform of bullous pemphigoid antigen 1, BPAG1-e (also known as BP2

39 gnized desmoplakin and plectin, and, weakly, bullous pemphigoid antigen 1.

40 Autoreactive T cells to an epitope of bullous pemphigoid antigen 180 kilodaltons were identifi

41 he beta4 integrin-associated plakin protein, bullous pemphigoid antigen 1e (BPAG1e) functions as a sc

42 integrin or knockdown of the plakin protein Bullous Pemphigoid Antigen 1e (BPAG1e).

43 Bullous pemphigoid antigen 2 (BPAG2) is targeted by auto

44 Skin grafts from mice expressing human bullous pemphigoid antigen 2 (hBPAG2) in epidermal basem

45 5 (p < 0.05), and in skin from patients with bullous pemphigoid antigen 2 mutations (n = 3) the count

46 roteins such as the integrin alpha6beta4 and bullous pemphigoid antigen 2 within the hemidesmosomes a

47 D97 is a component of the shed ectodomain of bullous pemphigoid antigen 2.

48 s reduced dynamics, and fails to recruit its bullous pemphigoid antigen binding partners.

49 The bullous pemphigoid antigen BPAG1 is required for keratin

50 ression of zinc finger protein 185 (ZNF185), bullous pemphigoid antigen gene (BPAG1), and prostate se

51 and attest to the importance of the 180-kDa bullous pemphigoid antigen in the attachment of the epid

52 A second bullous pemphigoid antigen of 180 kDa (BP180/BPAG2) is a

53 roteins and include desmoplakin, the 230 kDa bullous pemphigoid antigen, and envoplakin.

54 protein interacting with Nck (SPIN90/WISH), bullous pemphigoid antigen-1, and calcium channel beta2.

55 s of BMZ proteins: one enriched with the two bullous pemphigoid antigens (BP230, BP180) and one enric

56 he alpha6beta4 integrin, plectin, and BPAGs (bullous pemphigoid antigens).

57 Pemphigus and bullous pemphigoid are autoantibody-mediated blistering

58 Pemphigus and bullous pemphigoid are distinct autoimmune blistering di

59 n that contains all four of the well-defined bullous pemphigoid-associated antigenic sites.

60 has recently demonstrated that reactivity of bullous pemphigoid autoantibodies to the BP180 ectodomai

61 tandard techniques for detecting circulating bullous pemphigoid autoantibodies, including other enzym

62 h the 180 and 230 kDa proteins recognized by bullous pemphigoid autoantibodies, LABD97 has been thoug

63 t of the hemidesmosome plaque is the 230-kDa bullous pemphigoid autoantigen (BP230/BPAG1), which conn

64 salt-split indirect immunofluorescence, and bullous pemphigoid (BP) 230 and BP180-NC16A ELISAs.

65 Affiliated Hospitals with a new diagnosis of bullous pemphigoid (BP) between May 1, 1997 and Septembe

66 Bullous pemphigoid (BP) has been previously described to

67 Although predisposing factors for bullous pemphigoid (BP) have been recently established,

68 Bullous pemphigoid (BP) is a bullous dermatosis associat

69 Bullous pemphigoid (BP) is a subepidermal blistering dis

70 Bullous pemphigoid (BP) is a subepidermal blistering dis

71 Bullous pemphigoid (BP) is a subepidermal blistering dis

72 Bullous pemphigoid (BP) is an autoimmune bullous disease

73 Bullous pemphigoid (BP) is an autoimmune disease associa

74 Bullous pemphigoid (BP) is an autoimmune disease charact

75 Bullous pemphigoid (BP) is an autoimmune skin disease ch

76 Bullous pemphigoid (BP) is an autoimmune skin disease ch

77 Bullous pemphigoid (BP) is an autoimmune skin disease ch

78 Bullous pemphigoid (BP) is an autoimmune skin-blistering

79 Bullous pemphigoid (BP) is an autoimmune subepidermal bl

80 Bullous pemphigoid (BP) is an autoimmune subepidermal bl

81 Bullous pemphigoid (BP) is an autoimmune subepidermal bl

82 Bullous pemphigoid (BP) is an inflammatory subepidermal

83 Bullous pemphigoid (BP) is an inflammatory subepidermal

84 Bullous pemphigoid (BP) is by far the most frequent auto

85 Bullous pemphigoid (BP) is characterized by the depositi

86 tibodies from the sera of some patients with bullous pemphigoid (BP) react with a 180 kDa protein ter

87 Bullous pemphigoid (BP), a common autoimmune blistering

88 ation has long been a histologic hallmark of bullous pemphigoid (BP), a subepidermal autoimmune blist

89 ermal separation in an experimental model of bullous pemphigoid (BP), an autoimmune disease.

90 targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one

91 sera from patients with pemphigus vulgaris, bullous pemphigoid (BP), and chronic atopic and chronic

92 tients with a blistering skin disease called bullous pemphigoid (BP), is a transmembrane component of

93 rom patients with MMP, 1 of 50 patients with bullous pemphigoid (BP), none of 7 with pemphigus, and 3

94 e used IgG passive transfer murine models of bullous pemphigoid (BP), pemphigus foliaceus (PF), and p

95 The outcome of bullous pemphigoid (BP), the most frequent autoimmune sk

96 eurological disorders may be associated with bullous pemphigoid (BP).

97 reported sequence of the 180 kDa antigen in bullous pemphigoid (BPAg2).

98 ns regarding an experimental murine model of bullous pemphigoid by showing that the plasminogen/plasm

99 heir first year of life, with uncontrollable bullous pemphigoid, colitis, and proteinuria.

100 th BP underwent clinical evaluation with the Bullous Pemphigoid Disease Activity Index (BPDAI); and 3

101 d diagnosis of pemphigus vulgaris/foliaceus, bullous pemphigoid, epidermolysis bullosa acquisita, muc

102 tream from the MCW-1 domain, the predominant bullous pemphigoid epitope.

103 In the literature, patients with bullous pemphigoid have been reported to have itch witho

104 usion, there are now three bullous diseases, bullous pemphigoid, herpes gestationis, and cicatricial

105 Bullous pemphigoid is a blistering skin disease characte

106 Bullous pemphigoid is a blistering skin disorder with in

107 l patients with immunopathologic findings of bullous pemphigoid, itch, and no blisters.

108 In the inflammatory (bullous pemphigoid-like) EBA variant, autoantibody bindi

109 systemic lupus erythematosus (BSLE) (n = 3), bullous pemphigoid (n = 16), pemphigus (n = 11), and nor

110 Pemphigus vulgaris (n=40, USA and Japan), bullous pemphigoid (n=40, USA), and healthy donors (n=55

111 ostic assays and expertise and classified as bullous pemphigoid or epidermolysis bullosa acquisita.

112 stemic lupus erythematosus patients (n = 3), bullous pemphigoid patients (n = 15), and normal humans

113 T cells from eight of 12 bullous pemphigoid patients, all of whom had circulating

114 sease-specific autoantibodies in the sera of bullous pemphigoid patients.

115 e examined the autoimmune T cell response in bullous pemphigoid patients.

116 Sera from patients with bullous pemphigoid, pemphigus vulgaris, and cicatricial

117 reas the predominant epitope identified with bullous pemphigoid sera is located in the noncollagenous

118 Of 50 randomly selected bullous pemphigoid sera tested, 47 (94%) were positive i

119 Interestingly, all three of the bullous pemphigoid sera that were negative in this assay

120 inducing a skin disease that closely mimics bullous pemphigoid, supporting the hypothesis that epito

121 icture may be indistinguishable from that of bullous pemphigoid, the latter being the most common aut

122 p randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or mor

123 mmon in elderly patients, including scabies, bullous pemphigoid, transient acantholytic dermatosis, a

124 Earlier preliminary studies in humans with bullous pemphigoid, which is also associated with excess

125 The most common of these diseases is bullous pemphigoid, which mainly affects older people an